Latest From DalCor Pharmaceuticals
Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.
The commercial future of Merck & Co's CETP inhibitor anacetrapib is still in limbo as the 9% reduction in the risk of CV events seen in REVEAL underwhelms. Filings look unlikely.
- In Vitro Diagnostics
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- DalCor Pharmaceuticals
- Senior Management
Robert McNeil, CEO
Michael Dixon, CFO
Donald M Black, MD, CMO
Louise Proulx, PhD, Chief Dev. Officer
- Contact Info
Phone: (514) 564-6474
Sherbrooke St. West, Ste. 408
Montreal, H3A 2R7
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.